Search Results - "Arii, Shigeki"

Molecularly targeted therapy for hepatocellular carcinoma by Tanaka, Shinji, Arii, Shigeki

“…Accumulated understanding of the molecular pathways regulating cancer progression has led to the development of novel targeted therapies. Hepatocellular…”
Get full text

Molecular Targeted Therapies in Hepatocellular Carcinoma by Tanaka, Shinji, Arii, Shigeki

“…In vivo tumor progression requires the supply of oxygen and nutrition by neovasculature. Hepatocellular carcinoma (HCC) is one of the typical tumors with…”
Get full text

miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma by Furuta, Mayuko, Kozaki, Ken-ich, Tanaka, Shinji, Arii, Shigeki, Imoto, Issei, Inazawa, Johji

“…MicroRNAs (miRNAs) are a class of small non-coding RNAs that, in general, negatively regulate gene expression. They have been identified in various tumor…”
Get full text

Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) by Kokudo, Norihiro, Hasegawa, Kiyoshi, Akahane, Masaaki, Igaki, Hiroshi, Izumi, Namiki, Ichida, Takafumi, Uemoto, Shinji, Kaneko, Shuichi, Kawasaki, Seiji, Ku, Yonson, Kudo, Masatoshi, Kubo, Shoji, Takayama, Tadatoshi, Tateishi, Ryosuke, Fukuda, Takashi, Matsui, Osamu, Matsuyama, Yutaka, Murakami, Takamichi, Arii, Shigeki, Okazaki, Masatoshi, Makuuchi, Masatoshi

“…The 3rd version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of…”
Get full text

The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma by Furuta, Mayuko, Kozaki, Ken-ichi, Tanimoto, Kousuke, Tanaka, Shinji, Arii, Shigeki, Shimamura, Teppei, Niida, Atsushi, Miyano, Satoru, Inazawa, Johji

“…MicroRNAs (miRNAs) are key post-transcriptional regulators of gene expression and commonly deregulated in carcinogenesis. To explore functionally crucial…”
Get full text

Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies by Tanaka, Shinji, Arii, Shigeki

“…Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and its incidence is still increasing. While the primary curative treatment for…”
Get full text

Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan by Ikai, Iwao, Arii, Shigeki, Okazaki, Masatoshi, Okita, Kiwamu, Omata, Masao, Kojiro, Masamichi, Takayasu, Kenichi, Nakanuma, Yasuni, Makuuchi, Masatoshi, Matsuyama, Yutaka, Monden, Morito, Kudo, Masatoshi

“…In the 17th Nationwide Follow‐up Survey of Primary Liver Cancer in Japan, 18 213 individuals were newly registered as patients with primary liver cancer at 645…”
Get full text

Development of evidence‐based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan by Makuuchi, Masatoshi, Kokudo, Norihiro, Arii, Shigeki, Futagawa, Shunji, Kaneko, Shuichi, Kawasaki, Seiji, Matsuyama, Yutaka, Okazaki, Masatoshi, Okita, Kiwamu, Omata, Masao, Saida, Yukihisa, Takayama, Tadatoshi, Yamaoka, Yoshio

“…The Clinical Practice Guidelines for Hepatocellular Carcinoma (HCC), the first evidence‐based guidelines for the treatment of HCC in Japan, were compiled by an…”
Get full text

Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009) by Arii, Shigeki, Sata, Michio, Sakamoto, Michiie, Shimada, Mitsuo, Kumada, Takashi, Shiina, Shuichiro, Yamashita, Tatsuya, Kokudo, Norihiro, Tanaka, Masatoshi, Takayama, Tadatoshi, Kudo, Masatoshi

“…Hepatocellular carcinoma (HCC) is responsible for approximately 600 000–700 000 deaths worldwide. It is highly prevalent in the Asia–Pacific region and Africa,…”
Get full text

Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines by Takayasu, Kenichi, Arii, Shigeki, Kudo, Masatoshi, Ichida, Takafumi, Matsui, Osamu, Izumi, Namiki, Matsuyama, Yutaka, Sakamoto, Michiie, Nakashima, Osamu, Ku, Yonson, Kokudo, Norihiro, Makuuchi, Masatoshi

“…Background & Aims Transcatheter arterial chemoembolization with lipiodol (TACE) is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable…”
Get full text

Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey by Eguchi, Susumu, MD, Kanematsu, Takashi, MD, Arii, Shigeki, MD, Okazaki, Masatoshi, MD, Okita, Kiwamu, MD, Omata, Masao, MD, Ikai, Iwao, MD, Kudo, Masatoshi, MD, Kojiro, Masamichi, MD, Makuuchi, Masatoshi, MD, Monden, Morito, MD, Matsuyama, Yutaka, MD, Nakanuma, Yasuni, MD, Takayasu, Kenichi, MD

“…Background Although a surgical resection is an important modality for the treatment of hepatocellular carcinoma (HCC), the impact of the operative method on…”
Get full text

Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients by Takayasu, Kenichi, Arii, Shigeki, Ikai, Iwao, Omata, Masao, Okita, Kiwamu, Ichida, Takafumi, Matsuyama, Yutaka, Nakanuma, Yasuni, Kojiro, Masamichi, Makuuchi, Masatoshi, Yamaoka, Yoshio

“…Background & Aims: To elucidate the survival of the patients with unresectable hepatocellular carcinoma (HCC) who underwent transcatheter arterial lipiodol…”
Get full text

Report of the 18th follow-up survey of primary liver cancer in Japan by Ikai, Iwao, Kudo, Masatoshi, Arii, Shigeki, Omata, Masao, Kojiro, Masamichi, Sakamoto, Michiie, Takayasu, Kenichi, Hayashi, Norio, Makuuchi, Masatoshi, Matsuyama, Yutaka, Monden, Morito

“…In the 18th Nationwide Follow‐Up Survey of Primary Liver Cancer in Japan, 20 753 people were newly registered as patients with primary liver cancer at 544…”
Get full text

Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis by Ito, Hiromitsu, Tanaka, Shinji, Akiyama, Yoshimitsu, Shimada, Shu, Adikrisna, Rama, Matsumura, Satoshi, Aihara, Arihiro, Mitsunori, Yusuke, Ban, Daisuke, Ochiai, Takanori, Kudo, Atsushi, Arii, Shigeki, Yamaoka, Shoji, Tanabe, Minoru

“…Patients with pancreatic cancer typically develop tumor invasion and metastasis in the early stage. These malignant behaviors might be originated from cancer…”
Get full text

Hypervascular Hepatocellular Carcinoma: Correlation between Biologic Features and Signal Intensity on Gadoxetic Acid―enhanced MR Images by KITAO, Azusa, MATSUI, Osamu, KITA, Ryuichi, ARII, Shigeki, YONEDA, Norihide, KOZAKA, Kazuto, KOBAYASHI, Satoshi, KODA, Wataru, GABATA, Toshifumi, YAMASHITA, Tatsuya, KANEKO, Shuichi, NAKANUMA, Yasuni

“…To analyze the correlation among biologic features, tumor marker production, and signal intensity at gadoxetic acid-enhanced MR imaging in hepatocellular…”
Get full text

Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging and alpha‐fetoprotein predict prognosis of early‐stage hepatocellular carcinoma by Yamashita, Taro, Kitao, Azusa, Matsui, Osamu, Hayashi, Takehiro, Nio, Kouki, Kondo, Mitsumasa, Ohno, Naoki, Miyati, Tosiaki, Okada, Hikari, Yamashita, Tatsuya, Mizukoshi, Eishiro, Honda, Masao, Nakanuma, Yasuni, Takamura, Hiroyuki, Ohta, Tetsuo, Nakamoto, Yasunari, Yamamoto, Masakazu, Takayama, Tadatoshi, Arii, Shigeki, Wang, XinWei, Kaneko, Shuichi

“…The survival of patients with hepatocellular carcinoma (HCC) is often individually different even after surgery for early‐stage tumors. Gadolinium ethoxybenzyl…”
Get full text

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma by Arao, Tokuzo, Ueshima, Kazuomi, Matsumoto, Kazuko, Nagai, Tomoyuki, Kimura, Hideharu, Hagiwara, Satoru, Sakurai, Toshiharu, Haji, Seiji, Kanazawa, Akishige, Hidaka, Hisashi, Iso, Yukihiro, Kubota, Keiichi, Shimada, Mitsuo, Utsunomiya, Tohru, Hirooka, Masashi, Hiasa, Yoichi, Toyoki, Yoshikazu, Hakamada, Kenichi, Yasui, Kohichiroh, Kumada, Takashi, Toyoda, Hidenori, Sato, Shuichi, Hisai, Hiroyuki, Kuzuya, Teiji, Tsuchiya, Kaoru, Izumi, Namiki, Arii, Shigeki, Nishio, Kazuto, Kudo, Masatoshi

“…The response rate to sorafenib in hepatocellular carcinoma (HCC) is relatively low (0.7%‐3%), however, rapid and drastic tumor regression is occasionally…”
Get full text

Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma by Ohata, Yoshiteru, Shimada, Shu, Akiyama, Yoshimitsu, Mogushi, Kaoru, Nakao, Keisuke, Matsumura, Satoshi, Aihara, Arihiro, Mitsunori, Yusuke, Ban, Daisuke, Ochiai, Takanori, Kudo, Atsushi, Arii, Shigeki, Tanabe, Minoru, Tanaka, Shinji

“…Antiangiogenic therapy is initially effective for several solid tumors including hepatocellular carcinoma; however, they finally relapse and progress,…”
Get full text

Surgeons' involvement in COVID-19 treatment: a practice by a regional core hospital in Japan to avoid physician burnout by Matsui, Yugo, Yao, Siyuan, Kumode, Takashi, Tanino, Keisuke, Mizuno, Ryosuke, Ogoshi, Yusuke, Honma, Shusaku, Murakami, Teppei, Kan, Takatsugu, Nakajima, Sanae, Harada, Takehisa, Oh, Koji, Nakamura, Takehiro, Konishi, Hiroki, Arii, Shigeki

“…To prevent task accumulation on certain divisions, our institution developed a unique system of allocating inpatient treatment of COVID-19 patients to doctors…”
Get full text

Anatomic resection reduces the recurrence of solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion by Kudo, Atsushi, M.D., Ph.D, Tanaka, Shinji, M.D., Ph.D, Ban, Daisuke, M.D., Ph.D, Matsumura, Satoshi, M.D., Ph.D, Irie, Takumi, M.D., Ph.D, Nakamura, Noriaki, M.D., Ph.D, Arii, Shigeki, M.D., Ph.D

“…Abstract Background In patients with solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion, it is unknown whether the initial anatomic…”
Get full text